There are now 3 randomized, multicenter, US FDA investigational device exemption, industry-sponsored studies comparing arthroplasty with anterior cervical discectomy and fusion (ACDF) for single-level cervical disease with 2 years of follow-up. These 3 studies evaluated the Prestige ST, Bryan, and ProDisc-C artificial discs. The authors analyzed the combined results of these trials.
A total of 1213 patients with symptomatic, single-level cervical disc disease were randomized into 2 treatment arms in the 3 randomized trials. Six hundred twenty-one patients received an artificial cervical disc, and 592 patients were treated with ACDF. In the three trials, 94% of the arthroplasty group and 87% of the ACDF group have completed 2 years of follow-up. The authors analyzed the 2-year data from these 3 trials including previously unpublished source data. Statistical analysis was performed with fixed and random effects models.
The authors' analysis revealed that segmental sagittal motion was preserved with arthroplasty (preoperatively 7.26° and postoperatively 8.14°) at the 2-year time point. The fusion rate for ACDF at 2 years was 95%. The Neck Disability Index, 36-Item Short Form Health Survey Mental, and Physical Component Summaries, neck pain, and arm pain scores were not statistically different between the groups at the 24-month follow-up. The arthroplasty group demonstrated superior results at 24 months in neurological success (RR 0.595, I2 = 0%, p = 0.006). The arthroplasty group had a lower rate of secondary surgeries at the 2-year time point (RR 0.44, I2 = 0%, p = 0.004). At the 2-year time point, the reoperation rate for adjacent-level disease was lower for the arthroplasty group when the authors analyzed the combined data set using a fixed effects model (RR 0.460, I2 = 2.9%, p = 0.030), but this finding was not significant using a random effects model. Adverse event reporting was too heterogeneous between the 3 trials to combine for analysis.
Both anterior cervical discectomy and fusion as well as arthroplasty demonstrate excellent 2-year surgical results for the treatment of 1-level cervical disc disease with radiculopathy. Arthroplasty is associated with a lower rate of secondary surgery and a higher rate of neurological success at 2 years. Arthroplasty may be associated with a lower rate of adjacent-level disease at 2 years, but further follow-up and analysis are needed to confirm this finding.
Abbreviations used in this paper: ACDF = anterior cervical discectomy and fusion; BMI = body mass index; IDE = investigational device exemption; MCS = Mental Component Summary; NDI = neck disability index; NNT = number needed to treat; PCS = Physical Component Summary; ROM = range of motion; RR = relative risk; SF-36 = 36-Item Short Form Health Survey; VAS = visual analog scale; WMD = weighted mean difference.
* Drs. Upadhyaya and Wu contributed equally to this work
Address correspondence to: Jau-Ching Wu, M.D., Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital Room 509, 17F, No. 201, Shih-Pai Road, Sec. 2, Beitou, Taipei 11217, Taiwan. email: email@example.com.
Please include this information when citing this paper: published online December 23, 2011; DOI: 10.3171/2011.6.SPINE10623.
GoffinJVan CalenberghFvan LoonJCaseyAKehrPLiebigK: Intermediate follow-up after treatment of degenerative disc disease with the Bryan Cervical Disc Prosthesis: single-level and bi-level. Spine (Phila Pa 1976)28:2673–26782003
HellerJGSassoRCPapadopoulosSMAndersonPAFesslerRGHackerRJ: Comparison of BRYAN cervical disc arthroplasty with anterior cervical decompression and fusion: clinical and radiographic results of a randomized, controlled, clinical trial. Spine (Phila Pa 1976)34:101–1072009
KangHParkPLa MarcaFHollisterSJLinCY: Analysis of load sharing on uncovertebral and facet joints at the C5–6 level with implantation of the Bryan, Prestige LP, or ProDisc-C cervical disc prosthesis: an in vivo image-based finite element study. Neurosurg Focus28:6E92010
LiberatiAAltmanDGTetzlaffJMulrowCGøtzschePCIoannidisJP: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ339:b27002009
MummaneniPVHaidRW: The future in the care of the cervical spine: interbody fusion and arthroplasty. Invited submission from the Joint Section Meeting on Disorders of the Spine and Peripheral Nerves, March 2004. J Neurosurg Spine1:155–1592004
MurreyDJanssenMDelamarterRGoldsteinJZiglerJTayB: Results of the prospective, randomized, controlled multicenter Food and Drug Administration investigational device exemption study of the ProDisc-C total disc replacement versus anterior discectomy and fusion for the treatment of 1-level symptomatic cervical disc disease. Spine J9:275–2862009
TumialánLMPanJRodtsGEMummaneniPV: The safety and efficacy of anterior cervical discectomy and fusion with polyetheretherketone spacer and recombinant human bone morphogenetic protein-2: a review of 200 patients. J Neurosurg Spine8:529–5352008